Hyperion Partners’s AbbVie ABBV Stock Holding History

Hyperion Partners’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$404K	Buy	2,045 +1	+0%	+$187	0.26%	39
2024 Q2	$351K	Buy	2,044 +181	+10%	+$30K	0.25%	42
2024 Q1	$339K	Buy	1,863 +2	+0.1%	+$345	0.25%	44
2023 Q4	$288K	Sell	1,861 -114	-6%	-$16.6K	0.23%	49
2023 Q3	$294K	Sell	1,975 -10	-0.5%	-$1.47K	0.25%	48
2023 Q2	$267K	Buy	1,985 +29	+1%	+$4.25K	0.23%	50
2023 Q1	$312K	Sell	1,956 -1,307	-40%	-$200K	0.28%	44
2022 Q4	$527K	Buy	+3,263	New	+$500K	0.5%	28

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Hyperion Partners's ABBV Position: Q3 2024 in Review

Hyperion Partners increased its AbbVie (ABBV) stake by 0.05% in Q3 2024, buying an estimated $187 and bringing the position to 2,045 shares worth $404K. The position accounts for 0.26% of the portfolio, ranked #39.

Hyperion Partners first reported a position in ABBV in Q4 2022 and has held it in 8 quarters since. The position peaked at $527K in Q4 2022. 3,504 funds tracked by Wall St. Rank hold ABBV as of Q3 2024.

Hyperion Partners held 2,045 shares of AbbVie worth $404K as of Q3 2024.
Hyperion Partners bought 1 AbbVie share in Q3 2024, an estimated $187.
AbbVie made up 0.26% of Hyperion Partners's portfolio in Q3 2024, its #39 holding.
Hyperion Partners first reported a position in AbbVie in Q4 2022 and has held it in 8 quarters since.
Hyperion Partners's AbbVie position peaked at $527K in Q4 2022.
3,504 funds tracked by Wall St. Rank held AbbVie as of Q3 2024.

Based on Hyperion Partners's 13F filing for Q3 2024, filed 9 Oct 2024.